Literature DB >> 23112047

Role of Pin1 protein in the pathogenesis of nonalcoholic steatohepatitis in a rodent model.

Yusuke Nakatsu1, Yuichiro Otani, Hideyuki Sakoda, Jun Zhang, Ying Guo, Hirofumi Okubo, Akifumi Kushiyama, Midori Fujishiro, Takako Kikuch, Toshiaki Fukushima, Haruya Ohno, Yoshihiro Tsuchiya, Hideaki Kamata, Akiko Nagamachi, Toshiya Inaba, Fusanori Nishimura, Hideki Katagiri, Shin-ichiro Takahashi, Hiroki Kurihara, Takafumi Uchida, Tomoichiro Asano.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a disorder characterized by simultaneous fat accumulation and chronic inflammation in the liver. In this study, Pin1 expression was revealed to be markedly increased in the livers of mice with methionine choline-deficient (MCD) diet-induced NASH, a rodent model of NASH. In addition, Pin1 KO mice were highly resistant to MCD-induced NASH, based on a series of data showing simultaneous fat accumulation, chronic inflammation, and fibrosis in the liver. In terms of Pin1-induced fat accumulation, it was revealed that the expression levels of peroxisome proliferator-activated receptor α and its target genes were higher in the livers of Pin1 KO mice than in controls. Thus, resistance of Pin1 KO mice to hepatic steatosis is partially attributable to the lack of Pin1-induced down-regulation of peroxisome proliferator-activated receptor α, although multiple other mechanisms are apparently involved. Another mechanism involves the enhancing effect of hematopoietic Pin1 on the expressions of inflammatory cytokines such as tumor necrosis factor and monocyte chemoattractant protein 1 through NF-κB activation, eventually leading to hepatic fibrosis. Finally, to distinguish the roles of hematopoietic or nonhematopoietic Pin1 in NASH development, mice lacking Pin1 in either nonhematopoietic or hematopoietic cells were produced by bone marrow transplantation between wild-type and Pin1 KO mice. The mice having nonhematopoietic Pin1 exhibited fat accumulation without liver fibrosis on the MCD diet. Thus, hepatic Pin1 appears to be directly involved in the fat accumulation in hepatocytes, whereas Pin1 in hematopoietic cells contributes to inflammation and fibrosis. In summary, this is the first study to demonstrate that Pin1 plays critical roles in NASH development. This report also raises the possibility that hepatic Pin1 inhibition to the appropriate level might provide a novel therapeutic strategy for NASH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23112047      PMCID: PMC3531766          DOI: 10.1074/jbc.M112.397133

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

1.  Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins.

Authors:  X Z Zhou; O Kops; A Werner; P J Lu; M Shen; G Stoller; G Küllertz; M Stark; G Fischer; K P Lu
Journal:  Mol Cell       Date:  2000-10       Impact factor: 17.970

Review 2.  Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics.

Authors:  Kun Ping Lu
Journal:  Cancer Cell       Date:  2003-09       Impact factor: 31.743

3.  The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults.

Authors:  Paola Zacchi; Monica Gostissa; Takafumi Uchida; Clio Salvagno; Fabio Avolio; Stefano Volinia; Ze'ev Ronai; Giovanni Blandino; Claudio Schneider; Giannino Del Sal
Journal:  Nature       Date:  2002-10-02       Impact factor: 49.962

4.  Toll-like receptor ligands directly promote activated CD4+ T cell survival.

Authors:  Andrew E Gelman; Jidong Zhang; Yongwon Choi; Laurence A Turka
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

5.  The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein.

Authors:  P J Lu; G Wulf; X Z Zhou; P Davies; K P Lu
Journal:  Nature       Date:  1999-06-24       Impact factor: 49.962

6.  Mice lacking Pin1 develop normally, but are defective in entering cell cycle from G(0) arrest.

Authors:  F Fujimori; K Takahashi; C Uchida; T Uchida
Journal:  Biochem Biophys Res Commun       Date:  1999-11-30       Impact factor: 3.575

7.  Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.

Authors:  Emilia Ip; Geoff Farrell; Pauline Hall; Graham Robertson; Isabelle Leclercq
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

8.  A human peptidyl-prolyl isomerase essential for regulation of mitosis.

Authors:  K P Lu; S D Hanes; T Hunter
Journal:  Nature       Date:  1996-04-11       Impact factor: 49.962

9.  Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA.

Authors:  Akihide Ryo; Futoshi Suizu; Yasuhiro Yoshida; Kilian Perrem; Yih-Cherng Liou; Gerburg Wulf; Robert Rottapel; Shoji Yamaoka; Kun Ping Lu
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

Review 10.  The prolyl isomerase Pin1 in breast development and cancer.

Authors:  Gerburg Wulf; Akihide Ryo; Yih-Cherng Liou; Kun Ping Lu
Journal:  Breast Cancer Res       Date:  2003-01-28       Impact factor: 6.466

View more
  15 in total

1.  Prolyl isomerase Pin1 negatively regulates AMP-activated protein kinase (AMPK) by associating with the CBS domain in the γ subunit.

Authors:  Yusuke Nakatsu; Misaki Iwashita; Hideyuki Sakoda; Hiraku Ono; Kengo Nagata; Yasuka Matsunaga; Toshiaki Fukushima; Midori Fujishiro; Akifumi Kushiyama; Hideaki Kamata; Shin-Ichiro Takahashi; Hideki Katagiri; Hiroaki Honda; Hiroshi Kiyonari; Takafumi Uchida; Tomoichiro Asano
Journal:  J Biol Chem       Date:  2015-08-14       Impact factor: 5.157

2.  The prolyl isomerase Pin1 increases β-cell proliferation and enhances insulin secretion.

Authors:  Yusuke Nakatsu; Keiichi Mori; Yasuka Matsunaga; Takeshi Yamamotoya; Koji Ueda; Yuki Inoue; Keiko Mitsuzaki-Miyoshi; Hideyuki Sakoda; Midori Fujishiro; Suguru Yamaguchi; Akifumi Kushiyama; Hiraku Ono; Hisamitsu Ishihara; Tomoichiro Asano
Journal:  J Biol Chem       Date:  2017-05-31       Impact factor: 5.157

3.  Pin1 Inhibitor Juglone Exerts Anti-Oncogenic Effects on LNCaP and DU145 Cells despite the Patterns of Gene Regulation by Pin1 Differing between These Cell Lines.

Authors:  Ryuhei Kanaoka; Akifumi Kushiyama; Yasuyuki Seno; Yusuke Nakatsu; Yasuka Matsunaga; Toshiaki Fukushima; Yoshihiro Tsuchiya; Hideyuki Sakoda; Midori Fujishiro; Takeshi Yamamotoya; Hideaki Kamata; Akio Matsubara; Tomoichiro Asano
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

4.  Brown Algae Polyphenol, a Prolyl Isomerase Pin1 Inhibitor, Prevents Obesity by Inhibiting the Differentiation of Stem Cells into Adipocytes.

Authors:  Atsuko Suzuki; Toshiyuki Saeki; Hiroko Ikuji; Chiyoko Uchida; Takafumi Uchida
Journal:  PLoS One       Date:  2016-12-30       Impact factor: 3.240

Review 5.  Prolyl isomerase Pin1: a promoter of cancer and a target for therapy.

Authors:  Yang Chen; Ya-Ran Wu; Hong-Ying Yang; Xin-Zhe Li; Meng-Meng Jie; Chang-Jiang Hu; Yu-Yun Wu; Shi-Ming Yang; Ying-Bin Yang
Journal:  Cell Death Dis       Date:  2018-08-29       Impact factor: 8.469

6.  Pathological Role of Pin1 in the Development of DSS-Induced Colitis.

Authors:  Yasuka Matsunaga; Shun Hasei; Takeshi Yamamotoya; Hiroaki Honda; Akifumi Kushiyama; Hideyuki Sakoda; Midori Fujishiro; Hiraku Ono; Hisanaka Ito; Takayoshi Okabe; Tomoichiro Asano; Yusuke Nakatsu
Journal:  Cells       Date:  2021-05-17       Impact factor: 6.600

7.  Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus.

Authors:  Shirong Qiang; Yusuke Nakatsu; Yasuyuki Seno; Midori Fujishiro; Hideyuki Sakoda; Akifumi Kushiyama; Keiichi Mori; Yasuka Matsunaga; Takeshi Yamamotoya; Hideaki Kamata; Tomoichiro Asano
Journal:  Diabetol Metab Syndr       Date:  2015-11-19       Impact factor: 3.320

Review 8.  Physiological and Pathogenic Roles of Prolyl Isomerase Pin1 in Metabolic Regulations via Multiple Signal Transduction Pathway Modulations.

Authors:  Yusuke Nakatsu; Yasuka Matsunaga; Takeshi Yamamotoya; Koji Ueda; Yuki Inoue; Keiichi Mori; Hideyuki Sakoda; Midori Fujishiro; Hiraku Ono; Akifumi Kushiyama; Tomoichiro Asano
Journal:  Int J Mol Sci       Date:  2016-09-07       Impact factor: 5.923

9.  Protective Effect of Sex Hormone-Binding Globulin against Metabolic Syndrome: In Vitro Evidence Showing Anti-Inflammatory and Lipolytic Effects on Adipocytes and Macrophages.

Authors:  Hiroki Yamazaki; Akifumi Kushiyama; Hideyuki Sakoda; Midori Fujishiro; Takeshi Yamamotoya; Yusuke Nakatsu; Takako Kikuchi; Sunao Kaneko; Hirotoshi Tanaka; Tomoichiro Asano
Journal:  Mediators Inflamm       Date:  2018-06-25       Impact factor: 4.711

Review 10.  Natural Products to Fight Cancer: A Focus on Juglans regia.

Authors:  Elena Catanzaro; Giulia Greco; Lucia Potenza; Cinzia Calcabrini; Carmela Fimognari
Journal:  Toxins (Basel)       Date:  2018-11-14       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.